factive

(redirected from Gemifloxacin mesylate)
Also found in: Medical.

factive

(ˈfæktɪv)
adj
(Logic) logic linguistics philosophy (of a linguistic context) giving rise to the presupposition that a sentence occurring in that context is true, as John regrets that Mary did not attend
References in periodicals archive ?
Gemifloxacin Mesylate (Figure 1) is a synthetic broad-spectrum antibacterial agent for oral administration.
The IUPAC name of Gemifloxacin Mesylate is 7-[(4Z)-3-(Aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanesulfonic acid.
The aim of the present research was the rapid and sensitive determination and quantification of Gemifloxacin Mesylate in its bulk and pharmaceutical preparation with lower consumption of solvents using reverse phase (RP)-UPLC-UV in addition to its validation with respect to International Conference on Harmonization (ICH) guidelines.
Gemifloxacin mesylate (GMF) is (R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cydopropyl-6- fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid methanesulfonate, and moxifloxacin (MOX) is {1-cyclopropyl-7-[2,8-diazobicyclo (4.3.0) nonane]-6-fluoro-8-methoxy-1,4 dihydro-4-oxo-3-quinoline carboxylic acid} (Scheme 1) [1].
Pharmaceutical grade gemifloxacin mesylate (GMF) was supplied by Al-Obour Pharmaceutical & Chemical Industries Company, Egypt, and its potency was 99.99 [+ or -] 0.39%.
Gemifloxacin mesylate (GMF) is (R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid methanesulfonate.
Patanaik, "Difference spectrophotometric determination of gemifloxacin mesylate in tablet formulation," Asian Journal of Biochemical and Pharmaceutical Research, vol.
Summary: A sequential injection analysis (SIA) with chemiluminescence detection has been proposed for the determination of the antibiotic gemifloxacin mesylate (GFX).
Keywords: Silver nanoparticle; Gemifloxacin mesylate; Luminol- potassium ferricyanide system; Sequential injection analysis; Chemiluminescence
During the first quarter of 2007, the company expects to record approximately $12 million in revenue from ANTARA and approximately $11 million in revenues from FACTIVE (gemifloxacin mesylate) tablets.
FACTIVE (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity.
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI), Waltham, Mass., has completed enrollment in its Phase IV post-marketing trial for its fluoroquinolone antibiotic, FACTIVE (gemifloxacin mesylate) tablets.